HyTerra backs white hydrogen to pick the low-hanging decarbonisation fruits
White hydrogen has amongst the lowest cost and carbon intensity of all hydrogen sources It can deliver immediate decarbonisation goals by supplying existing sectors such [more…]
Broker downgrades The Reject Shop, but still gives it a big price target
Jarden Research downgrades The Reject Shop from a Buy to Overweight But price target is still set high at $5.80, versus current price of $3.30 [more…]
Sheep-derived products propel Aroa’s global growth in soft tissue regeneration
AROA Biosurgery continues to expand its product line in regenerative tissue repair on back of positive clinical results Using ovine forestomach matrix, Aroa’s ECM technology [more…]
MoneyTalks: Luke Winchester’s three picks for a bit of local AI
MoneyTalks is Stockhead’s regular drill down into what stocks investors are looking at right now. We’ll tap our extensive list of experts to hear what’s [more…]
Rise and Shine: Everything you need to know before the ASX opens
Good morning everyone, and welcome to 12 June, 2024 – an important day in the history of the world for a variety of mildly [more…]
Equinox ties up more Brazilian REE tenure, expanding Mata da Corda by 15pc
Equinox Resources’ Mata de Corda REE project in Brazil increased by 15pc Project landholding now almost 1000km2 Sample results from new tenure due next month [more…]
Long Shortz with Althea Group: Why this stock is looking towards FY25
Stockhead’s Fraser Palamara sits down with Althea Group (ASX:AGH) CEO Josh Fegan to get the short end of the long story on the company’s latest news. [more…]
Closing Bell: ASX buried under -1.3pc as iron ore miners and goldies take a beating
Aussie shares slipped over 1pc after the King’s Birthday long weekend Mining and Real Estate sectors were the biggest losers among all 11 sectors Chinese [more…]
Riversgold outlines a large copper anomaly at Tambourah
Historical copper intersections at the Tambourah project have explorer Riversgold pleased One particular intercept measured to 30.5m at 1.1% copper Chairman David Lenigas says boots [more…]
US FDA extends orphan drug designation for Race Oncology’s lead asset
US FDA extends orphan drug designation to Race’s re-formulated RC220 bisantrene drug product for treatment of Acute Myeloid Leukemia Orphan drug designation has a [more…]
